Pregnancy-Induced Hypertension - Symptoms, Causes, Treatment & Prevention

```html

Overview

Pregnancy‑induced hypertension (PIH), also called gestational hypertension, is a condition in which a woman develops new‑onset high blood pressure (≥140/90 mm Hg) after 20 weeks of gestation without the presence of proteinuria or other systemic signs of pre‑eclampsia. PIH is distinct from chronic hypertension (high blood pressure that predates pregnancy) and from pre‑eclampsia, which adds organ dysfunction.

• Who it affects: Any pregnant woman can develop PIH, but the risk rises with certain demographic and medical factors (see “Causes and Risk Factors”).
• Prevalence: According to the World Health Organization, gestational hypertension occurs in roughly 6‑8 % of all pregnancies worldwide, making it one of the most common hypertensive disorders of pregnancy.<sup>1</sup>
• Why it matters: While many cases resolve after delivery, PIH can progress to pre‑eclampsia, lead to preterm birth, and increase the long‑term risk of cardiovascular disease for both mother and child.<sup>2</sup>

Symptoms

Unlike chronic hypertension, PIH often presents without obvious signs, which is why routine prenatal blood‑pressure checks are essential. When symptoms do occur, they may be subtle or mistaken for normal pregnancy changes.

• Elevated blood pressure: Measured ≥140 mm Hg systolic or ≥90 mm Hg diastolic on two separate occasions at least 4 hours apart.
• Headache: Persistent, throbbing, or “pressure‑like” headache that does not improve with rest or acetaminophen.
• Visual disturbances: Blurred vision, flashing lights, “looking at a kaleidoscope,” or temporary loss of vision.
• Upper abdominal or right‑upper‑quadrant pain: Often described as a dull ache beneath the ribs, sometimes confused with heartburn.
• Swelling (edema): Sudden, rapid swelling of the face, hands, or feet that is disproportionate to the typical swelling of pregnancy.
• Nausea or vomiting: New‑onset, especially if accompanied by other symptoms.
• Shortness of breath: Unexplained difficulty breathing, especially at rest.
• Reduced fetal movement: Noticeable decrease in the baby’s activity count.

Many women with PIH experience **no symptoms**; identification relies on regular blood‑pressure monitoring.

Causes and Risk Factors

The exact pathophysiology of PIH is not fully understood, but current research points to abnormal development of the placental vasculature, leading to systemic endothelial dysfunction and vasoconstriction.

Key risk factors

• First pregnancy (nulliparity): The immune system’s first exposure to paternal antigens may contribute.
• Maternal age: Women younger than 20 years or older than 35 years have higher incidence.<sup>3</sup>
• Obesity: Pre‑pregnancy BMI ≥ 30 kg/m² roughly doubles the risk.<sup>4</sup>
• Family history of hypertension or pre‑eclampsia: Genetic predisposition.
• Pre‑existing medical conditions: Diabetes mellitus, renal disease, autoimmune disorders (e.g., lupus), and chronic hypertension.
• Multiple gestation: Twins or higher-order multiples increase placental demand.
• Assisted reproductive technologies (ART): Higher rates of hypertensive disorders have been reported.
• Socio‑economic factors: Limited access to prenatal care, poor nutrition, and high stress levels.

Diagnosis

Diagnosis is made clinically and through a series of investigations to differentiate PIH from chronic hypertension and pre‑eclampsia.

Blood‑pressure measurement

• Measured in the seated position after 5 minutes of rest.
• Both arms should be checked; the higher reading is used.
• Two elevated readings ≥140/90 mm Hg taken at least 4 hours apart (or on separate days) after 20 weeks gestation.

Laboratory tests

• Urinalysis: To rule out proteinuria (<300 mg/24 h) which would suggest pre‑eclampsia.
• Complete blood count (CBC): Look for thrombocytopenia.
• Serum creatinine & liver enzymes (AST/ALT): Assess renal and hepatic function.
• Uric acid: Elevated levels may herald progression to pre‑eclampsia.

Fetal assessment

• Ultrasound: Checks growth, amniotic fluid volume, and placental health.
• Doppler studies: Assess uterine artery blood flow; abnormal indices can indicate increased risk.
• Non‑stress test (NST) or biophysical profile (BPP): Evaluate fetal well‑being when maternal disease escalates.

Treatment Options

Treatment balances maternal safety with fetal maturity. The primary goals are to control blood pressure, prevent progression to pre‑eclampsia, and prolong pregnancy to achieve fetal development when possible.

Medications

• Methyldopa: First‑line antihypertensive in pregnancy; safe for mother and fetus.
• Labetalol: Beta‑blocker with alpha‑blocking activity; commonly used for rapid BP control.
• Nifedipine (extended‑release): Calcium‑channel blocker; alternative when labetalol is contraindicated.
• Hydralazine: IV agent for severe hypertension (>160/110 mm Hg) in the hospital setting.

ACE inhibitors, ARBs, and direct renin inhibitors are **contraindicated** because of teratogenic risk.

Non‑pharmacologic measures

• Rest and activity modification: Bed rest is no longer routinely recommended, but moderate activity within tolerance is encouraged.
• Dietary sodium restriction: Limit to <1500 mg/day if BP is borderline.
• Hydration: Adequate fluid intake (≈2 L/day) unless edema is severe.

Procedural and delivery considerations

• Hospital admission: For severe BP, rapid rise, or concerning labs.
• Corticosteroids: Betamethasone 12 mg IM q24 h × 2 doses if delivery before 34 weeks is anticipated, to enhance fetal lung maturity.
• Timing of delivery:
  • ≥37 weeks: Induction or C‑section recommended once BP is controlled.
  • 34‑36 weeks: Delivery considered if BP ≥160/110 mm Hg, worsening labs, or fetal compromise.
  • <37 weeks with stable disease: Expectant management with close monitoring.
• Magnesium sulfate: Not required for PIH alone but indicated if the condition evolves to pre‑eclampsia with severe features to prevent seizures.

Living with Pregnancy‑Induced Hypertension

Effective self‑management helps keep blood pressure stable and reduces anxiety.

• Home monitoring: Use a validated automatic cuff; record readings twice daily (morning & evening). Share logs with your obstetric team.
• Nutrition: Follow a balanced diet rich in fruits, vegetables, whole grains, and lean protein. The DASH (Dietary Approaches to Stop Hypertension) pattern is pregnancy‑friendly.
• Weight gain: Aim for the Institute of Medicine (IOM) recommended weight gain based on pre‑pregnancy BMI (e.g., 25‑35 lb for normal BMI).
• Physical activity: 150 minutes of moderate‑intensity aerobic activity per week (e.g., brisk walking) unless otherwise instructed.
• Stress reduction: Prenatal yoga, deep‑breathing exercises, or guided meditation can lower sympathetic tone.
• Medication adherence: Take antihypertensives exactly as prescribed; never stop abruptly.
• Fetal movement tracking: Begin counting kicks after 28 weeks; report a decrease of >2 hours of inactivity.
• Regular prenatal visits: Attend every scheduled appointment; additional visits may be scheduled for close BP monitoring.

Prevention

While PIH cannot always be prevented, modifiable risk factors can be addressed before and early in pregnancy.

• Pre‑conception health optimization: Achieve a healthy BMI, control pre‑existing diabetes or hypertension, and cease smoking.
• Low‑dose aspirin: CDC and ACOG recommend 81 mg daily from 12‑28 weeks gestation for women at high risk of pre‑eclampsia/PIH (e.g., previous PIH, chronic hypertension, renal disease).<sup>5</sup>
• Calcium supplementation: 1 g elemental calcium daily for women with low dietary calcium intake may lower risk.<sup>6</sup>
• Early prenatal care: First‑trimester blood‑pressure measurement establishes a baseline.
• Nutrition counseling: Limiting excessive weight gain and sodium intake.

Complications

If left uncontrolled, PIH can progress to serious maternal and fetal outcomes.

• Progression to pre‑eclampsia or eclampsia: Development of proteinuria, organ dysfunction, or seizures.
• Placental abruption: Premature separation of placenta leading to hemorrhage.
• Fetal growth restriction (FGR): Chronic uteroplacental insufficiency reduces nutrient/oxygen delivery.
• Preterm birth: Needed for maternal safety, but poses neonatal respiratory and neurodevelopmental risks.
• Maternal stroke or myocardial infarction: Rare but high‑mortality events.
• Long‑term cardiovascular disease: Women with a history of PIH have a 2‑3‑fold increased risk of hypertension, coronary artery disease, and stroke later in life.<sup>7</sup>

When to Seek Emergency Care

References

1. World Health Organization. Hypertensive disorders of pregnancy. WHO Fact Sheet, 2022.
2. American College of Obstetricians and Gynecologists. Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2020.
3. U.S. Centers for Disease Control and Prevention. Pregnancy and Birth Statistics. 2023.
4. JAMA Network. “Maternal Obesity and Risk of Hypertensive Disorders of Pregnancy.” 2021.
5. American College of Cardiology. Low‑Dose Aspirin for Prevention of Preeclampsia. 2021 Guideline.
6. National Institutes of Health. “Calcium Supplementation for Prevention of Preeclampsia.” 2020.
7. Hypertension Research. “Long‑Term Cardiovascular Risk After Gestational Hypertension.” 2022.

```